A recent 2024 review highlights that early-phase clinical studies using EPHX2 inhibitors (such as GSK2256294) are underway in acute kidney injury and diabetic nephropathy, aimed at reversing oxidative injury and preserving tubular function [72]. The gene discussed is EPHX2; the disease is diabetic kidney disease.